Synthesis and biological evaluation of all possible inosine-mixed cyclic dinucleotides that activate different hSTING variants

Zhenghua Wang,Cancan Zhao,Chuanlin Wang,Hang Zhang,Dejun Ma,Qiangzhe Zhang,Xin Wen,Luyuan Li,Zhen Xi

DOI: https://doi.org/10.1016/j.bmc.2020.115899

2021-01-01

Abstract:<p>Cyclic dinucleotides (CDNs) could activate stimulator of interferon genes (STING) protein to produce type I interferon and other pro-inflammation cytokines in mammalian cells. To explore new types of potentially efficient STING activators targeting all five major hSTING variants (WT, R232H, HAQ, AQ and R293Q), we here reported the synthesis of a total of 19 inosine-containing CDNs based on the combinations of hypoxanthine with four natural bases (A, G, C and U) and three phosphodiester linkage backbones (3′-3′, 2′-3′, 2′-2′). The IFN-β induction results showed that all of the 2′-3′ and 2′-2′ CDNs linked by inosine and purine nucleosides favored the stacking interaction with Y167 and R238 residues of hSTING protein, and several CDNs constructed by hypoxanthine and pyrimidine like c[I(2′,5′)U(2′,5′)] could also activate all five hSTING variants. The molecular dynamic simulation and the isothermal titration calorimetric (ITC) assay further demonstrated the potential of cAIMP isomers with 2′-5′ phosphate to form the hydrogen binding with R232 and R238 residues of hSTING in an entropically driven manner compared to cGAMP isomers. It would be promising to exploit novel inosine-mixed CDNs as activators of hSTING variants in immune therapy.</p>

biochemistry & molecular biology,chemistry, medicinal, organic

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop new cyclic dinucleotides (CDNs) as effective activators of human STING protein variants (including WT, R232H, HAQ, AQ, and R293Q) for immunotherapy. Specifically, the authors synthesized 19 possible inosine - containing cyclic dinucleotides. These compounds are based on the combinations of hypoxanthine with four natural bases (A, G, C, U) and the combinations of three phosphodiester bond backbones (3′ - 3′, 2′ - 3′, 2′ - 2′). The study aims to evaluate the activation ability of these compounds on different human STING variants, especially whether they can activate all five major human STING variants, thereby improving the efficacy in immunotherapy.

By synthesizing these inosine - containing CDNs and using the dual - luciferase reporter system to evaluate their activation effects on different STING variants in HEK293T cells, a biological evaluation was also carried out in the THP - 1 cell line. The research results show that all 2′ - 3′ and 2′ - 2′ type CDNs, when they are linked by inosine and purine nucleotides (G, A or I), exhibit excellent activation activity for all five STING variants. In addition, the study also found that CDNs containing inosine and uracil (such as 10d, 13d, 16c) can also activate STING - mediated immune responses, especially 10d can activate all five STING variants.

In conclusion, this study has developed new inosine - containing CDNs. These compounds have a good activation effect on all five major human STING variants, providing a potential new tool for improving the effect of immunotherapy.